Orbital leiomyoma

Summary

Orbital leiomyoma (MONDO:0018885) is a disease. A subtype of eye neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: <1 / 1 000 000 (Worldwide) [Orphanet-validated]

Clinical features

Epidemiology

Prevalence records

2 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Cases/families		26	Worldwide	Validated
Point prevalence	<1 / 1 000 000		Worldwide	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	orbital leiomyoma
Mondo ID	MONDO:0018885
Orphanet	52994
ICD-11	614302400
SNOMED CT	719045009
UMLS	C4305000
MedGen	930669
GARD	0018845
Is cancer (heuristic)	no

Disease family

This is a subtype of eye neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › disorder of orbital region › eye disorder › eye neoplasm › orbital leiomyoma

Related subtypes (12): eyelid neoplasm, ocular cancer, ring dermoid of cornea, intraocular medulloepithelioma, combined hamartoma of the retina and retinal pigment epithelium, conjunctival tumor, lacrimal gland neoplasm, uvea neoplasm, retina neoplasm, cornea neoplasm, benign neoplasm of eye, ocular surface squamous neoplasia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.